Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron Group PLC treats first patient in retinitis pigmentosa trial

The procedure involves a single injection of hRPC cells under the retina
ReNeuron Group PLC treats first patient in retinitis pigmentosa trial
RP leads to progressive loss of sight due to photoreceptor cells in the retina becoming damaged and eventually dying.

Stem cell specialist ReNeuron Group PLC (LON:RENE) has treated its first patient in a phaseI/II US trial of its retinitis pigmentosa (RP) cell therapy remedy.

The procedure, involving a single injection of hRPC cells under the retina, was conducted at Massachusetts Eye and Ear in Boston, a teaching affiliate of Harvard Medical School and a specialist in retinal degeneration. The patient was discharged from hospital that day.

RP leads to progressive loss of sight due to photoreceptor cells in the retina becoming damaged and eventually dying. 

ReNeuron’s Human Retinal Progenitor Cells (hRPCs) have shown an ability to protect the host retina from further degeneration and also potentially treat any of the genetic variants of RP.

Fifteen patients will be treated with  hRPC in the trial, the company’s first in the US. The hRPC programme has US fast-track status and Orphan Drug Designation in both the US and Europe.

ReNeuron aims to file for a Phase II/III clinical trial in the second half of 2017 dependent on how this trial goes.  

Olav Hellebo, ReNeuron’s chief executive said:  “Retinal degenerative diseases represent extremely attractive targets for cell therapy approaches and our programme targeting RP benefits from a number of key competitive advantages in terms of the potential mechanisms of action of our hRPC cells and the potential speed of clinical development to market for this programme.

“With the start of this study, we are also delighted to have commenced clinical development activities in the US, a major target market."

PhilW.jpg
Why Invest In ReNeuron Group Plc? Read More Here

Register here to be notified of future RENE Company articles
View full RENE profile

ReNeuron Group Plc Timeline

Video
October 28 2016
Article
October 28 2016

Related Articles

Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
AZN2.jpg
September 20 2016
The absence of a discount suggests there is a healthy appetite for the equity.
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.